Lund-Johansen P, Omvik P
Scand J Urol Nephrol Suppl. 1984;79:87-91.
Twelve males with moderately severe essential hypertension (mean arterial pressure [MAP] ranging 113-162 mmHg) were studied at rest supine and sitting and during bicycle exercise (50, 100 and 150 W). Intraarterial blood pressure (BP), and heart rate (HR) were recorded continuously. Cardiac output (CO) was measured by dye dilution (Cardiogreen). After 6-8 months (enalapril dose 10-40 mg daily) patients were restudied. BP fell in all patients, at rest sitting from 184/107 mmHg to 150/87 (-19%) and during 100 W from 223/117 to 194/98 mmHg (p less than 0.001). Pretreatment total peripheral resistance index (TPRI) was greatly increased in all patients and fell from 4137 to 3651 dyn s cm-5 m2 (-16%) (p less than 0.05). No significant changes were seen in CO, HR or stroke volume. No side effects were seen. It is concluded that enalapril reduces BP in patients with moderately severe hypertension at rest and during exercise due to reduction in TPRI without significant changes in CO or HR.
对12名患有中度严重原发性高血压(平均动脉压[MAP]范围为113 - 162 mmHg)的男性进行了研究,研究内容包括仰卧位和坐位休息时以及自行车运动(50、100和150瓦)期间的情况。连续记录动脉内血压(BP)和心率(HR)。通过染料稀释法(Cardiogreen)测量心输出量(CO)。6 - 8个月后(依那普利剂量为每日10 - 40毫克)对患者进行再次研究。所有患者的血压均下降,坐位休息时从184/107 mmHg降至150/87 mmHg(-19%),在100瓦运动时从223/117 mmHg降至194/98 mmHg(p < 0.001)。所有患者治疗前的总外周阻力指数(TPRI)均大幅升高,从4137降至3651 dyn s cm⁻⁵ m²(-16%)(p < 0.05)。CO、HR或每搏输出量未见显著变化。未观察到副作用。结论是,依那普利通过降低TPRI降低了中度严重高血压患者休息时和运动期间的血压,而CO或HR无显著变化。